Categories
Health

A Few Covid Vaccine Recipients Developed a Uncommon Blood Dysfunction

On January 29th, Dr. Bussel Mrs. Legaspis doctor, Dr. Niriksha Chandrani, an email labeled “My Strong Recommendations,” stated that he was “very afraid” that Ms. Legaspi would have a cerebral haemorrhage and recommended a different course of treatment. Dr. Chandrani, chief oncology physician at Elmhurst, realized that Dr. Bussel was a leading authority on platelet disorder, and she took his advice.

She had spent several sleepless nights worrying about Ms. Legaspi.

“I didn’t want her to die,” said Dr. Chandrani.

Recognition…about Luz Legaspi

A day later, Ms. Legaspi’s platelet count had reached 6,000: “Slow but steady progress,” said Dr. Bussel. The next morning it was 40,000, which got them out of the most perilous zone. Two days later, on February 1, there were 71,000.

It’s impossible to tell if the new treatments worked, if the first started, or if she recovered on its own. But on February 2, she went home from the hospital to the Queens apartment she shares with her daughter and 7-year-old grandson. On February 4, her daughter said Ms. Legaspi’s platelet count was 293,000.

Another vaccine recipient, Sarah C., 48, a teacher in Arlington, Texas, received the Moderna vaccine on January 3rd. She asked not to use her full name to protect her privacy.

Two weeks later, she began to have profuse vaginal bleeding. After two days, she saw her obstetrician, who ordered blood tests and other tests. A few hours later he called and urged her to go straight to the emergency room. He was stunned, hoping it was a lab mistake, but her blood count showed no platelets. She had had an exam less than a week before the vaccination and blood test results were completely normal.

Categories
Business

Fauci method to two-dose vaccine is true, says Richard Besser

Richard Besser, who served as deputy director of the Centers for Disease Control and Prevention under former President Barack Obama, said the U.S. should continue to focus on giving patients both doses of the Covid-19 vaccine despite the slow rollout .

On CNBC’s “The News with Shepard Smith,” Besser agreed with the comments made by Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, had handed in on Monday. During a Covid-19 briefing at the White House, Fauci said staying on course for two doses offers us the clearest avenue for protecting people from the virus and its growing number of variants.

“I would go with Dr. Fauci on that case,” Besser said. “I have concerns that if we take a single dose, we may offer humans a sub-optimal level of protection.”

Both the Pfizer and Moderna vaccines have been approved by the Food and Drug Administration based on the protection they provide after two doses at different times. Due to the slower-than-expected introduction of the vaccine and the spread of Covid-19 variants across the country, some scientists have recommended distributing single vaccines to more people rather than double-dose fewer patients.

Besser, who now serves as President and CEO of the Robert Wood Johnson Foundation, also said it was too early for states to open bars and restaurants to larger groups of people. He said while evidence shows we can safely open schools, indoor social gatherings could lead to larger outbreaks “if we drop our guard”.

Categories
Health

AstraZeneca races to adapt Covid vaccine as South Africa halts rollout

The dose of Oxford University / AstraZeneca COVID-19 vaccine will be displayed from its box on January 2nd, 2021 at the Princess Royal Hospital, Haywards Heath, West Sussex, UK.

Gareth Fuller | Reuters

Drug maker AstraZeneca is making efforts to adapt its Covid-19 vaccine in light of new variants of the virus. The process is becoming more urgent after a small study found it less effective at protecting against the more virulent strain discovered in South Africa.

The country said it will end the use of the shot in its vaccination program after a study published on Sunday that has not yet been peer-reviewed found the vaccine offered “minimal protection” against mild to moderate illnesses caused by the South African variant will.

Researchers from the University of Witwatersrand and others in South Africa, as well as the University of Oxford, found the study was small, with only about 2,000 volunteers, with a mean age of 31. Oxford University said: “Protection from moderate to severe illness, hospitalization or death could not be assessed in this study because the target group was exposed to such a low risk.”

The vaccine manufacturers had already started developing second-generation Covid vaccines, which will target new variants of the virus. Experts say it shouldn’t be too difficult to tweak existing vaccines to cover mutations, and that they could be adjusted within six weeks.

Sarah Gilbert, professor of vaccinology at Oxford University who developed the vaccine with AstraZeneca, said Sunday that “efforts are being made to develop a new generation of vaccines that will allow protection on new variants as booster jabs redirect if this is the case. ” it turns out that it is necessary to do so. “

“We are working with AstraZeneca to optimize the pipeline that would be required for a strain change should one become necessary. This is the same problem all vaccine developers face and we will continue to monitor the emergence of new variants that arise in the readiness for a future change of burden.

The variant, officially known as the B.1.351 mutation, was first detected in South Africa in October 2020 and has since become dominant in the country.

Several cases have also been found elsewhere of health officials making efforts to stop the spread of the mutation, which has been found to be more contagious. There were already concerns that this variant might be more resistant to coronavirus vaccines developed last year.

With the use of the AstraZeneca-Oxford University jab stopped, the South African government will instead offer vaccines made by Johnson & Johnson and Pfizer.

In late January, Johnson & Johnson reported that its single-dose shot was 57% effective in one of its clinical trials in South Africa, where almost all Covid-19 cases (95%) were due to variant B infection. 1,351 descent. For comparison, the vaccine was found to be 72% effective in the US arm of the study.

Pfizer-BioNTech and Moderna have both reported early signs that their vaccinations offer protection against new known variants of the virus found in South Africa and the UK

On Friday, Oxford University released details of a separate study showing the vaccine was effective against a variant of the virus that was first discovered in south-east England and has now become the dominant strain in the UK

Andrew Pollard, professor of pediatric infection and immunity and lead investigator of the Oxford vaccine study, said data from studies of its vaccine in the UK “shows that the vaccine protects not only against the original pandemic virus, but also against the novel variant B.1.1 .7, which caused the rise in disease across the UK from late 2020. “

Categories
Business

AstraZeneca’s Vaccine Does Not Work Effectively Towards Virus Variant in South Africa

South Africa stopped using the AstraZeneca-Oxford coronavirus vaccine on Sunday after it was found the vaccine did not protect volunteers in clinical trials from mild or moderate illnesses caused by the more contagious variant of the virus first observed there.

The results were a devastating blow to the country’s efforts to fight the pandemic.

Scientists in South Africa said Sunday that a similar problem existed for people infected with previous versions of the coronavirus: the immunity they gained naturally did not seem to protect them from mild or moderate cases than what they were known to have Variant were re-infected as B.1.351.

The developments that occurred almost a week after a million doses of the AstraZeneca-Oxford vaccine hit South Africa were a huge blow to the country, where more than 46,000 people are known to have died from the virus.

They were also another sign of the dangers posed by new mutations in the coronavirus. Variant B.1.351 has spread to at least 32 countries, including the USA.

The number of cases evaluated as part of the studies outlined by South African scientists on Sunday was small, making it difficult to determine exactly how effective the vaccine might or might not be against the variant.

And because the clinical trial participants studied were relatively young and likely not to get seriously ill, it was impossible for the scientists to determine whether the variant affected the AstraZeneca-Oxford vaccine’s ability to protect against severe Covid-19, hospitalization, or death.

However, the scientists said they believed the vaccine might protect against more severe cases based on the immune responses seen in blood samples from people who were given it. If further studies show this is the case, South African health officials will consider resuming use of the AstraZeneca-Oxford vaccine, they said.

The new research results were not published in a scientific journal. The discovery that the AstraZeneca-Oxford product has only minimal effectiveness in preventing mild and moderate cases of the new variant contributed to the growing evidence that B.1.351 makes current vaccines less effective.

Pfizer and Moderna have both said that preliminary laboratory studies show that while their vaccines are still protective, they are less effective against B.1.351. Novavax and Johnson & Johnson have also sequenced test samples from their clinical trial participants in South Africa, where B.1.351 caused the vast majority of cases, and both reported less efficacy than in the US.

“These results are really a reality check,” said Shabir Madhi, a virologist at Witwatersrand University who conducted the AstraZeneca-Oxford vaccine study in South Africa, of the results released on Sunday.

The pause in the introduction of the AstraZeneca-Oxford vaccine in the country means that first deliveries are now being made in warehouses.

Instead, South African health officials said they would be vaccinating health workers with the Johnson & Johnson vaccine in the coming weeks, which has shown strong effectiveness in preventing severe cases and hospitalizations caused by the new variant.

Johnson & Johnson has applied for an emergency permit in South Africa. However, the local health authorities said that some health workers could receive the vaccine before its approval as part of an ongoing study.

In the AstraZeneca-Oxford study in South Africa, around 2,000 participants received either two doses of the vaccine or placebo injections.

There was virtually no difference in the number of people in the vaccine and placebo groups infected with B.1.351, suggesting that the vaccine did little to protect against the new variant. Nineteen of the 748 people in the group who received the vaccine were infected with the new variant, compared with 20 of 714 people in the group who were given a placebo.

This equates to a vaccine effectiveness of 10 percent, although the scientists didn’t have enough statistical confidence to know for sure whether that figure would apply to more people.

The researchers also conducted laboratory experiments on blood samples from people who had been vaccinated and found a significant reduction in the levels of activity of vaccine-generated antibodies to the B.1.351 variant compared to other lineages.

Aside from the disturbing news about the AstraZeneca-Oxford vaccine, Dr. Madhi on evidence that previous infection from previous versions of the coronavirus did not protect people in South Africa from variant B.1.351.

To determine who was previously infected with the coronavirus, the researchers tested blood samples from people who had participated in a study of the Novavax vaccine but who were given placebo shots rather than the vaccine itself.

The researchers compared the infection levels of the new variant in people who were shown to have previously had Covid-19 with the infection levels in people who did not and found no difference.

Dr. Madhi wrote on a slide presented on Sunday evening that “an earlier infection by ‘original’ variants of SARS-CoV-2 does NOT protect against mild and moderate Covid-19 from the B.1.351 variant”.

He said it was possible that the B.1.351 variant’s potential to evade immune responses in previously infected people was at least partially responsible for why South Africa has suffered such a devastating second wave of the virus in recent months.

Oxford University researchers admitted on Sunday that the vaccine offers “minimal protection” against mild or moderate cases with variant B.1.351. They are working on a new version of the vaccine that can protect against the most dangerous mutations of variant B.1.351 and hope that it will be ready in the fall.

“This study confirms that, as expected, the pandemic coronavirus will find ways to spread further in vaccinated populations,” Andrew Pollard, lead investigator for the Oxford vaccine study, said in a statement. “Given the encouraging results of other studies in South Africa using a similar viral vector, vaccines can continue to reduce the burden on health systems by preventing serious diseases.”

Moderna has also started developing a new form of its vaccine that can be used as a booster shot against the variant in South Africa.

B.1.351 has become the dominant form of the virus in South Africa and has been found in several dozen countries. A small number of cases have been reported in South Carolina, Maryland, and Virginia.

Scientists believe that B.1.351 is better able to evade antibodies produced by vaccines because it has acquired a mutation known as E484K that makes it difficult for antibodies to capture the virus and prevent it from entering cells.

Novavax said its vaccine was almost 50 percent effective in preventing Covid-19 in its South Africa study. Johnson & Johnson reported that its single vaccine was 57 percent effective in preventing moderate to severe Covid-19 in South Africa, although it still offered full protection against hospitalization and death after four weeks.

Another fast-spreading variant of the virus, known as B.1.1.7 and first identified in the UK, does not appear to affect the vaccines. All five leading vaccines, and most recently AstraZeneca’s product, were found to offer similar protection against B.1.1.7 when compared to previous lines of the virus.

AstraZeneca’s vaccine has been approved by around 50 countries, including the UK, which has found dozens of cases of the variant first seen in South Africa.

In the US, regulators are waiting for data from a large late-stage clinical trial of the AstraZeneca-Oxford vaccine, which is expected to be published in March.

Categories
Health

Covid instances are falling, however unequal vaccine entry threatens world restoration, WHO says

Worldwide Covid-19 cases are declining, but the uneven distribution of life-saving vaccines could prolong the global economic recovery and leave developing countries even further behind, the World Health Organization said on Wednesday.

In the week ending January 31, 3.7 million new global coronavirus cases were reported, a 13% decrease from the previous week. This emerges from the latest WHO situation report. Covid-19 deaths, which are a few weeks behind new cases, saw a slight 1% decrease over the week.

That’s good news when you consider that 5.5 million cases are injured each week worldwide, but more than 3 million new infections are “still a lot of people,” said Dr. Mike Ryan, Executive Director of the WHO Health Emergencies Program.

“The rain has subsided, but the sun isn’t shining yet,” Ryan said during a live Q&A session at the agency’s Geneva headquarters.

Health experts have warned that new, highly infectious variants of the virus, first identified in the UK, South Africa and Brazil, could already add fuel to furious outbreaks in countries around the world.

A faster transmitting virus could lead to more infections and would ultimately lead to more hospitalizations and deaths if it spreads uncontrollably. But even in areas where the variants have emerged, cases are declining, said Maria Van Kerkhove, director of the WHO’s Department of Emerging Diseases and Zoonosis.

In Great Britain, which identified variant B.1.1.7 in December, cases have decreased by 31% compared to the previous week, according to a WHO report. In South Africa, where a similar variant called B.1.351 was also discovered late last year, cases fell by 44%, the report said.

“This is important because people are scared when they hear mutations, mutants and variants,” said Kerkhove. “We can’t let go of our guard. We can’t let go.”

The emergence of new coronavirus variants did not surprise scientists, as it is normal for viruses to mutate as they spread. Experts fear that some of the strains, particularly variant B.1.351 found in South Africa, could pose a risk to the effectiveness of the vaccines and therapeutics currently available.

Drug makers have claimed that their shots should continue to work against the new variants, but health experts have stressed the importance of containing the spread of the virus to prevent further mutations while countries provide primary care with Covid-19 vaccines .

However, not all countries have had equal access to life-saving medicines.

Of the countries that have started dosed doses to their residents, most were in higher-income countries that claimed early delivery of vials through their own delivery agreements, warned WHO Director General Tedros Adhanom Ghebreyesus.

That’s a problem because the vaccines will eventually allow countries to reopen their economies without the risk of an increase in hospital stays and deaths from the virus, Ryan said Wednesday. WHO has voted for countries to sign up for COVAX, a global alliance they jointly lead and aim to deliver coronavirus vaccines to the world’s poorest countries.

The program hopes to deliver 2.3 billion cans by the end of this year. Earlier Wednesday, COVAX officials announced that they had so far provided at least 330 million doses to poorer countries, which are expected to be delivered in late February or early March. These early doses would be used to vaccinate the most vulnerable, such as healthcare workers.

Ryan said this would allow countries to reopen their economies without worrying about putting more strain on their hospital systems. However, this will only be possible if “we can deliver the minimum number of vaccine doses to all countries”.

“If we want our societies to be open, if we want to be on the path to normalizing and normalizing our way of life, we have to be fair in how we distribute the funds to live normally,” said Ryan. “Right now, the uneven distribution of vaccines means that not all societies have an equal chance to get back online, and that’s just not fair.”

– CNBC’s Holly Ellyatt and Reuters contributed to this report.

Categories
Business

Russian Marketing campaign Promotes Homegrown Vaccine and Undercuts Rivals

Intelligence officials in the United States noticed the first surge in Russia against Spanish-speaking communities in August when President Vladimir V. Putin announced that he had given Sputnik V approval. Since then, Russia’s campaign has intensified, said two intelligence officials, who spoke to the New York Times on condition of anonymity because they were not authorized to speak to reporters.

State Department officials described Russia’s campaign of influence as a combination of state-sponsored media in Russia, highlighting reports warning of the dangers of US vaccines and promoting reports enthusiastic about the Russian-made vaccine.

A report was distributed at the Foreign Ministry last month detailing Russia’s efforts, officials said. A department spokeswoman said Russia was trying to promote its own vaccine while trying to “sow suspicion of Western vaccines” in the US. The Foreign Ministry’s Global Engagement Center analyzed over 1,000 Russian-facing Twitter accounts and found that Spanish-language accounts showed the greatest engagement. Russia’s campaign, the spokeswoman said, “undermines collective global efforts to end the global pandemic.”

The campaign of influence in Mexico best understands the efforts of the branches with ties to the Kremlin. It was different from previous Russian disinformation campaigns that put false and misleading information online. As social media companies have become more aggressive to root out disinformation, Russian operations have focused on promoting selective news that bypasses the truth, rather than rejecting it.

The new approach has been particularly effective as the Spanish-language Twitter and Facebook accounts of Russia Today and Sputnik, two state-controlled media outlets, are consistently among the most influential in Latin America, First Draft researchers said. “They have cultivated a large audience and are consistently in the top 10 most shared stories or links,” Longoria said.

In a statement, Russia Today said: “The RT stories referenced form part of our coverage and have been reported by many other news outlets. Although The Times frames them as part of a “disinformation” campaign, it nowhere points to any errors, inaccuracies or falsehoods in these stories, thereby unduly affecting RT coverage. “Sputnik didn’t respond to a request for comment.

Categories
Health

Is Your Vaccine Card Selfie a Reward for Scammers? Perhaps

So you finally got a Covid-19 vaccine. It’s easy to take a photo of your vaccination card with your name and date of birth and the vaccine you had and post it on social media.

However, some experts warn that the information in the festive photo could expose you to identity theft or fraud.

“Unfortunately, your card has your full name and birthday and information about where you got your vaccine from,” the Better Business Bureau said last week. “If your social media privacy settings are not set high, you may be sharing valuable information that anyone can use.”

On Friday, the Federal Trade Commission followed suit: “You post a photo of your vaccination card on social media. Please – don’t do that! “it bluntly warned.” You could invite identity theft. “

Fraudsters can sometimes find out most of the digits of your Social Security number by knowing your date and place of birth. You can open new accounts on your behalf, claim your tax refund for yourself, and get involved in other identity thefts, said Maneesha Mithal, assistant director of the Federal Trade Commission’s privacy and identity protection division.

“Identity theft is like a puzzle made up of personal information,” said Ms. Mithal. “You don’t want to give identity thieves the parts they need to complete the picture. One of these pieces is your date of birth. “

But even if experts warn against giving your card away, chances are the information you are giving up has already been made available in other ways if you recorded your birthday elsewhere online – which most people likely have.

Avivah Litan, a senior analyst at research firm Gartner, said many Americans are vulnerable to multiple data breaches.

“Basically, the criminals already have pretty much every last name, first name and date of birth,” said Ms. Litan. “There have been so many hacks in the last 10 years. If you’re just looking for my name and birthday, you have it. “

Scammers and identity thieves often gradually collect information and clean up social media posts to create a file on a person’s life, including education, employment, and vacation spots. Publishing a date of birth will give you one of your most important personal tidbits.

While a name and date of birth aren’t all an identity thief would need in most cases to steal your identity, it makes it easier to reveal those details.

“Scammers are looking for personal identification information they can get from you – any kind of information to create a profile,” said Curtis W. Dukes, executive vice president of the Center for Internet Security.

A scammer could take advantage of fear of vaccine shortages or a slow distribution process by disguising himself as a government official claiming to need a credit card number to reserve a different dose or booster, Dukes said.

In such a “charged” atmosphere of bottlenecks, people could “fall for it and give up their credit cards or other information,” he said.

Ms. Litan said, “At least it will give bad actors a go-ahead to know who has been vaccinated. So you can use it for fraud purposes, to socially construct me and pay them for a booster shot that I will never get, or for valid commercial purposes that bypass normal US regulatory structures. “

Luscious teenagers post pictures of their driver’s licenses or study permits. Vacationers publish photos of their trips.

The vaccination cards are now another way to “share these milestones in our lives,” said Nita A. Farahany, professor of law and philosophy at Duke University School of Law.

However, she said one concern is that if vaccination status acts as a commodity that gives people access to workplaces, restaurants or events, the cards could be forged or replicated.

Someone who has not yet been vaccinated or does not wish to be vaccinated might “be tempted to forge a copy of these photos,” she said. “Or why wouldn’t a corporate scammer use the photos to create fakes to be sold to whoever they want?”

The Better Business Bureau in its warning cited newspaper reports in the UK that counterfeit vaccination cards were bought on eBay for about $ 6.

When asked about the reports, eBay said in a statement sent via email that it blocked and removed items that made false health claims.

A published vaccination card could also be the springboard for sophisticated social engineering or phishing ideas. Such programs were common during the pandemic.

Stacey Wood, a professor of psychology at Scripps College who has counseled older adults who are victims of fraud, cited what is known as grandparent fraud, in which a person posing as a law enforcement officer contacted an older adult and pretended to give them details about their grandchildren and to say they were in trouble and needed financial help.

“The typical consumer wouldn’t believe that scammers curated information about my life and used it to target me,” she said. “There’s so much going on in my practice right now and it’s just going to be a new thing.”

Cassie Christensen, a consultant at SecZetta who works with organizations to manage identity risk, said people who had their vaccination card issued could open themselves to a scammer posing as an officer trying to verify their identity to get them across inform medical concerns example, suspected new side effects.

The scam could include requests for more information to help them gain access to someone’s accounts, such as a mother’s maiden name or an address.

“You can also go to LinkedIn and find out where you work,” she said. “You can call these organizations and do a legitimate password reset.”

The pandemic and its fears would have created the perfect environment for it.

“It’s all very emotional stuff,” she said. “This is what hackers and phishers are looking for.”

With the distribution of vaccines unevenly, the maps have become a boastful point. Some use it on their dating profiles. Others are just excited to post good news after such a bad year.

“Some post it to say, ‘Look, I got it,” said Duke’s Dr. Farahany.

But what if there was another way of saying that? The Centers for Disease Control and Prevention believe it is. As part of his campaign to build confidence in the vaccines, sticker templates were created and many states, including Wisconsin, Georgia, Texas, Louisiana, New York, and Maryland, are distributing versions of them.

Public health officials are betting on the widespread use of stickers to impact people who may be afraid, indifferent to, or simply against vaccines. The stickers could contribute to so-called “social cascades” of behavior, similar to the way the “I voted” stickers promote voting, experts say.

“It helps encourage similar behavior in other people who may be watching,” said Dr. Tara Kirk Sell, a senior scientist at the Johns Hopkins Center for Health Security. “It’s really about telling others, ‘This is completely normal and that’s what people do.'”

The same behavior occurs when masks are used frequently, making more people feel less out of place wearing one. “We call this ‘social proof,'” said Dr. Wood. “Like, ‘I’ve done my patriotic duty, I’ve done my civic duty.'”

Stickers also don’t reveal personal information, another reason officials promote their use.

In Georgia, Attorney General Chris Carr this week urged people to show vaccination stickers and said he could “not stop them enough from posting their vaccination cards on social media” due to the risk of identity theft.

Also, “the stickers are really cool,” the FTC said on Friday.

Categories
World News

Is Your Vaccine Card Selfie a Reward for Scammers? Possibly.

So you finally got a Covid-19 vaccine. It’s easy to take a photo of your vaccination card with your name and date of birth and the vaccine you had and post it on social media.

However, some experts warn that the information in the festive photo could expose you to identity theft or fraud.

“Unfortunately, your card has your full name and birthday and information about where you got your vaccine from,” the Better Business Bureau said last week. “If your social media privacy settings are not set high, you may be sharing valuable information that anyone can use.”

On Friday, the Federal Trade Commission followed suit: “You post a photo of your vaccination card on social media. Please – don’t do that! “it bluntly warned.” You could invite identity theft. “

Fraudsters can sometimes find out most of the digits of your Social Security number by knowing your date and place of birth. You can open new accounts on your behalf, claim your tax refund for yourself, and get involved in other identity thefts, said Maneesha Mithal, assistant director of the Federal Trade Commission’s privacy and identity protection division.

“Identity theft is like a puzzle made up of personal information,” said Ms. Mithal. “You don’t want to give identity thieves the parts they need to complete the picture. One of these pieces is your date of birth. “

Categories
Health

Biden Covid response workforce holds briefing after J&J requests FDA OK for vaccine

[The stream is slated to start at 11 a.m. ET. Please refresh the page if you do not see a player above at that time.]

President Joe Biden’s Covid-19 Response Team will hold a briefing Friday on the coronavirus pandemic that left at least 455,875 Americans dead.

The briefing comes one day after Johnson & Johnson asked the Food and Drug Administration to approve the unique Covid-19 vaccine for use in the United States. The FDA has scheduled a meeting of its Advisory Committee on Vaccines and Related Biological Products in February 26 to discuss the vaccine, which could be distributed in the US as early as this month.

Federal and state officials are eagerly awaiting approval of J & J’s vaccine.Unlike Pfizer and Moderna’s vaccines, which require two doses three to four weeks apart, J & J’s drugs only require one dose , which makes logistics easier for healthcare providers.

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.

Categories
Health

Biden administration to ship troops to California to assist employees Covid vaccine websites

Secretary of Defense Lloyd Austin visits National Guard forces stationed in the U.S. Capitol and its vicinity on Capitol Hill in Washington, DC, on January 29, 2021.

Manuel Balce Ceneta | Getty Images

The Secretary of Defense has approved the deployment of more than 1,000 active troops to deliver Covid-19 vaccines in the United States, a member of President Joe Biden’s coronavirus response team said Friday.

Some of the troops will arrive in California next week within the next ten days and begin operations by February 15. Other states will follow. Andy Slavitt, a senior advisor to Biden’s Covid-19 response team who previously worked in the Obama administration, is told reporters.

“The vital role of the military in supporting sites will help vaccinate thousands of people every day and ensure that every American who wants a vaccine receives it,” he said during the White House news conference.

The Pentagon is working with the Federal Emergency Management Agency to expedite delivery of the shots, which were slower than expected.

This is a developing story. Please try again.